Kuboniswe ukuhlinzeka ngesisindo nokunciphisa ushukela wegazi
Ingabe ungumuntu oye waba nesifo sikashukela iminyaka eminingana futhi awukwazi ukulawula ushukela wakho futhi emithini yomlomo? Isifo sikashukela yisifo esiqhubekayo futhi ngezinye izikhathi ukulungiswa kwemithi yokwelashwa kudingeka kwenziwe ukuze kusize ukulawula ushukela wegazi.
Ngokuvamile, abantu abanesifo sikashukela bangazuza ngokusebenzisa imithi ejova (hhayi i-insulin) ngaphezu kwemithi yabo yomlomo.
Imithi engenayo i-insulin, ebizwa ngokuthi i-GLP-1 agonists (njenge-Byetta ne-Victoza), iye yaboniswa ukusiza ekunciphiseni ngemuva kokudla ushukela wegazi nokunciphisa isisindo.
Kuyini i-Bydureon?
Enye i-GLP-1 agonist, i-Bydureon, ifomu elide elibhekene ne-Byetta elinikezwa kanye ngeviki. I-Bydureon i-GLP-1 (i-peptide-i-glucagon-like peptide 1) i-agonist evuselela ukucinwa kwe-insulini lapho ihlangana ne-glucose.
Kuye kwaboniswa ukuthi kulondolozwa umsebenzi we-beta cell (amaseli e-beta enza i-insulin) futhi kuye kwafakazelwa ukukhuthaza ukulahlekelwa isisindo ngokubambezela ukukhushulwa kwesisu kanye nokwanda kwemizwa yokugcwele. Ucwaningo luye lwabonisa ukuthi abantu abathwala i-Bydureon balahlekelwa ngamaphilisi angamahlanu ngenyanga inyanga eyisithupha yokuthatha imithi futhi baboniswe ukuthi bayigcine ngonyaka.
Ucwaningo olusha lwe-AstraZeneca (abanikazi be-Bydureon) lubonisa ukuthi kukhishwa isikhathi esisodwa ngesonto ngokumiswa kwe-autoinjection kunikezwe ukunciphisa okukhulu kwe-HbA1c (-1.4 vs -1.0) kunokuba i-Byetta injection kabili ngosuku.
Iziguli ezingxenyeni ezizimele ze-autoinjection neqembu lakwa-Byetta lalinciphisa okufanayo ngesisindo somzimba esinesisindo (-1.5 kg vs. -1.9 kg, ngokulandelana; p-value = 0.4).
Ezinye izifundo ziye zabonisa ukuthi uma kuqhathaniswa ne-insulin, iziguli ezisebenzisa i-Bydureon zilahlekelwa isisindo-isinqumo esizimele sokulawula ushukela wegazi.
Ukulawulwa kwe-Sugar Sugar
Nakuba ukuhlolwa kwemitholampilo kubonise ukuthi ukwelashwa ne-Bydureon kungasiza ukunciphisa i-A1c ngamaphesenti angaba ngu-1.5, i-Bydureon ayisetshenziswanga njengokwelashwa kokuqala kwesifo sikashukela. Esikhundleni salokho, ngokuvamile kuvame ukusetshenziswa njenge-agent yesibili noma yesithathu ngokuhlanganiswa ne- metformin noma i-sulfonylurea.
Uma uthatha i-sulfonylurea, umthamo wakho ungadinga ukulungiswa ukuze unciphise ingozi ye- hypoglycemia . I-Bydureon kufanele isetshenziswe ngokuhambisana nokudla nokuzivocavoca futhi ayihloswanga ukuthi isetshenziswe njengesidakamizwa sokulahlekelwa isisindo.
Ukuthatha i-Bydureon
Ngaphambilini, i-Bydureon yayitholakale kuphela isebenzisa isiraphu esasiyindoda esinde futhi enzima. Nakuba umjovo wawukodwa kanye ngesonto, abanye abantu bakhononda ngokungahambi kahle. Kodwa-ke, manje i-Bydureon iyatholakala ukuze isetshenziswe nge-pen. Ipeni cishe lizokhululeka futhi likwazi ukulusebenzisa kangcono kune-syringe.
I-Bydureon kufanele ijowe ngaphansi kwesibunxele ibe ngamathishu amaningi futhi ingangeni kumisipha noma emithanjeni. Ungayifaka i-Bydureon ezindaweni ezifanayo ongayifaka i-insulin-isisu (izinyintshi ezimbili kude nenkipho yakho yesisu), amathanga angaphandle, izimpande zezingalo zakho ezingenhla. Ungasebenzisa indawo efanayo masonto onke, zama nje ukungasebenzisi indawo efanayo.
Ngezinye izikhathi abantu bazizwa bebuhlungu noma babomvu endaweni yokujova.
Shayela ngokushesha umhlinzeki wakho wezempilo uma unomunyu obukhulu, ukuvuvukala, izibhansela, isilonda esivulekile, noma isikhala somnyama endaweni yakho yokujova.
Ubani Okhethwe I-Bydureon?
Xoxa nomhlinzeki wakho wezokunakekelwa kwezempilo uma ungumuntu ozobhalwa yi-Bydureon. I-Bydureon ayihloswanga ukuthi isetshenziswe njengesidakamizwa sokulahlekelwa isisindo futhi ngokuvamile isetshenziselwa ngokuhambisana neminye imithi yesifo sikashukela. Uma ungumuntu onesifo sikashukela sohlobo lwesi-2 ogama lakhe likashukela egazini alikho emgomweni futhi angakwazi ukulahlekelwa isisindo , kunokuba i-Bydureon ingase ibe yindlela ongakhetha kuyo.
Ubani Akufanele Awathathe i-Bydureon?
Ezifundweni zezilwane, i-Bydureon yabangela amagundane ukuba ahlakulele izicubu zegciwane le-thyroid.
Ngakho-ke, i-Bydureon iphikisana neziguli ezinomlando womuntu siqu noma womndeni we-medullary umdlavuza we-thyroid (MTC) kanye neziguli ezine-Multiple Endocrine Neoplasia syndrome uhlobo 2 (MEN 2). Abantu abanomzwelo wokudlulela noma noma yiziphi izingxenye zomkhiqizo akufanele futhi bathathe i-Bydureon.
Ngaphambi kokuba uthathe i-Bydureon, kufanele utshele umhlinzeki wakho uma unomlando we-pancreatitis, amatshe ku-gallbladder yakho (gallstones), umlando wokudakwa ngokweqile, noma amazinga aphakeme egazi we-triglyceride njengoba i-Bydureon ingase ingasetshenziselwa wena. Uma uthatha i-Bydureon, uma uzwa ubuhlungu obukhulu besisu obungasuki, kufanele uxhumane nomhlinzeki wakho wezokunakekelwa kwempilo ngokushesha njengoba lokhu kungase kube uphawu lwe-pancreatitis. I-Bydureon ayihloselwe iziguli ezine-type 1 zesifo sikashukela.
Ingabe Lena Yona Yodwa Imithi Ejova Ngamaviki Kanye Kanye?
Njengamanje, i-Bydureon yiyona kuphela imithi ejova ngeviki elilodwa kuphela emakethe. Kodwa, ezinye izinkampani zisebenza ekufomeni futhi ziqhuba izivivinyo zomtholampilo. I-Bydureon imane nje isiqalo sokwemakethe yesifo sikashukela.
Okuqhamuka uma udla imishanguzo
Ngenxa yokuthi i-Bydureon ibambezela ukukhipha isisu, imiphumela emibi kakhulu ihlanganisa ukunxanxathela nokuhlanza. I-nausea ngokuvamile iyenzeka uma kuqala ukuqala imithi futhi yehla isikhathi esiningi lapho umzimba usebenzisa imithi. Ezinye imiphumela emibi zibandakanya ikhanda, isifo sohudo, ubomvu endaweni yomjovo.
> Imithombo:
> Wysham, uCarol, kanye. al. I-DURATION-NEO-1: ukunciphisa okukhulu kwe-HbA1c nokumiswa okwesikhashana uma ubhekene ne-autoinjector ipeni ngokuphindaphindiwe kabili nsuku zonke ku-type 2 yesifo sikashukela esingalawuleki. Ngo-Septhemba 29, 2014.
> I-Ahren, B & Schmitz, i-O. GLP-1 ye-receptor agonists kanye ne-DPP-4 inhibitors ekwelapheni uhlobo lwesifo sikashukela. I-Horm Metab Res. 2004 Nov-Dec; 36 (11-12): 867-76. September 24, 2014.
> Reid, uThimothewu, MD. Ukukhetha i-GLP-1 ye-receptor agonists noma i-DPP-4 inhibitors: enesisindo sobufakazi bemitholampilo. Association of American Diabetes Association. Septemba 25, 2014.
> Ukuphathwa Kwezokudla Nezidakamizwa. Umhlahlandlela wama-Bydureon . Septemba 25, 2014.